Stocktoria
Benitec Biopharma Inc. BNTC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-07-11
Benitec Biopharma Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $75,000 | $73,000 | $59,000 |
| R&D expense | $18.3M | $15.6M | $12.8M | $11.3M | $7.0M |
| Operating income | -$41.8M | -$22.5M | -$19.1M | -$17.9M | -$13.6M |
| Net income | -$37.9M | -$21.8M | -$19.6M | -$18.2M | -$13.9M |
| EPS (diluted) | $-1.05 | $-1.22 | $-14.12 | $-37.88 | $-3.23 |
| Operating cash flow | -$23.6M | -$19.4M | -$18.0M | -$15.9M | -$12.8M |
| Free cash flow | -$23.6M | -$19.6M | -$18.0M | -$15.9M | -$13.1M |
| Cash & equivalents | $97.7M | $50.9M | $2.5M | $4.1M | $19.8M |
| Total assets | $99.6M | $52.2M | $4.5M | $6.0M | $21.4M |
| Total liabilities | $2.3M | $5.0M | $4.3M | $3.1M | $1.4M |
| Shareholders' equity | $97.3M | $47.2M | $202,000 | $2.9M | $20.0M |
Source: SEC EDGAR filings · CIK 0001808898 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.